

Product Data Sheet

Product Name: Daunorubicin-Cytarabine Liposome

Cat. No.: GC79731

Chemical Properties

Cas. No. 1256639-86-7


Formula $C_{36}H_{42}N_4O_{15}$ M.Wt 770.74

Solubility Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure



Background

Cytarabine -daunorubicin (CPX 351) is a Liposomal formulation prepared from Cytarabine and Daunorubicin at a fixed synergistic molar ratio of 5:1. Cytarabine -daunorubicin improves secondary acute myeloid leukemia. Cytarabine -daunorubicin can be used in research related to secondary acute myeloid leukemia, high-risk myelodysplastic syndrome, and chronic myelomonocytic leukemia [1] [2].

In Vitro, Cytarabine-daunorubicin is 5 times more potent against FLT3-ITD leukemic blasts than against wild-type leukemic blasts^[1].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

References:

- [1]. Lancet JE, et al. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol. 2018;36(26):2684-2692.
- [2]. Peterlin P, et al. CPX 351 as first line treatment in higher risk MDS. A phase II trial by the GFM[J]. Blood, 2021, 138: 243.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA